Home > Companies > Sensyne Health

Sensyne Health

sensynehealth.com

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

8th International Conference on Bio-Sensing Technology

Conference

Related News

Cell and Gene Therapy, Diagnostics

VERTEX AND CRISPR THERAPEUTICS ANNOUNCE A LICENSING AGREEMENT TO HASTEN THE DEVELOPMENT OF HYPOIMMUNE CELL THERAPIES FOR TYPE 1 DIABETES

Businesswire | March 28, 2023

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D). “We have multiple programs in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune program, in preclinic...

Industrial Impact

KANE BIOTECH ANNOUNCES NEW COLLABORATION AGREEMENTS FOR PROSTHETIC JOINT INFECTION, EXPANDING ITS DISPERSINB® APPLICATIONS

Kane Biotech Inc. | February 11, 2022

Kane Biotech Inc. announces that it has signed collaboration agreements with Dr. James Doub, MD, Assistant Professor of Medicine, University of Maryland School of Medicine’s Institute of Human Virology, and the University of Texas Medical Branch (UTMB) to study the use of DispersinB® with Prosthetic Joint Infection (PJI) patients. The group is securing funding from the National Institutes of Health (NIH) for pre-clinical work to be done by Josh Wenke, a Professor in the Department of O...

Cell and Gene Therapy

HEALIVA® ACQUIRES CRITICAL CELL THERAPY MANUFACTURING ASSETS FROM B. BRAUN

Healiva | November 22, 2022

Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis de...

Medical

HTL ANNOUNCES ITS INCUBATOR'S EQUITY INVESTMENT IN GELMEDIX, AN EARLY-STAGE BIOTECH AIMING AT REVOLUTIONIZING OCULAR AND REGENERATIVE THERAPIES

HTL | March 14, 2022

HTL Biotechnology, a pioneer and world leader in the development and production of innovative pharmaceutical grade biopolymers, today announced its incubator's first equity investment in GelMEDIX Inc., an early-stage biotechnology company committed to developing the next generation of ocular and regenerative therapies. This investment supports continued development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therap...

Cell and Gene Therapy, Diagnostics